Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SNFCA 8.92 - Q3 filed with what I think are exceptional numbers for a $9 pps stock but wtfdik cause no one else seems to care???
Scott M. Quist, President of the Company, said, "Realizing our operational earnings decreased as compared to 2020, I am nevertheless very proud of the results for Quarter 3 and year-to-date 2021. I believe our financial results represent a very solid performance by our teams accomplished despite a continuingly difficult operational environment. Every business segment delivered impressive results.
https://docoh.com/news/benzinga/24100551/security-national-financial?fromCompany=318673
SKAS 3.40 - .19 EPS, 4.40 BV, miniscule 1M O/S. What's not to like here?
Revenue of $1.5 Million in 2021 up 101.4% Versus $721,000 in 2020
Net Income of $197,000 in 2021 Versus Net Income of $6,000 in 2020
https://www.otcmarkets.com/stock/SKAS/news/SAKER-AVIATION-SERVICES-INC-ANNOUNCES-FINANCIAL-RESULTSFOR-THE-THREE-MONTHS-ENDED-SEPTEMBER-30-2021?id=330983
TLIS 5.36 - granted EUA for covid testing...
https://docoh.com/filing/1584751/0001564590-21-056276/TLIS-8K/file/2
Any thoughts? I was attracted to the current cashfat position.
CYAN 3.40 - joined you with a first position. Solid all-around fundamentals and awaiting the upcoming cc...
Cyanotech will host a virtual broadcast at 8:00 PM EST on Thursday, November 11, 2021 to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to questions@cyanotech.com before 12 p.m. (noon) EST on Thursday, November 11, 2021. The Company will respond only to relevant questions relating to the Company’s second quarter fiscal 2022 financial performance and will not be accepting any questions or comments during the broadcast.
CPSS 7.40 - still cheap...with a current .52 quarterly eps, 9 months = 1.12 eps, current share buybacks with a positively giddy management, Solid Balance Sheet, and very bright outlook...
https://docoh.com/news/benzinga/23672261/cps-announces-third-quarter?fromCompany=889609
Can CPSS top their .52 eps in Q4...
GOOD LORD!!!!!+!!
WE ARE RICH!!!!
Winning Strategy...or...another probable case of one talking when one should be LISTENING, ya think...
APT - still a solid value stock. I'd be a buyer in the $4's...but unless we get another 'virus'-kookout, which is very likely as there are an INFINITE number of viruses, the heydey is over for APT imo.
APT 6.28 - released a stinker with .06 eps on sizeable reduction in revenue and even stinkier guidance? I shorted a few...
Management believes that gross profit margin will be negatively affected in 2021 as a result of changes in product mix, as the need for face masks and face shields which have a higher gross profit margin than our other products, declines from the surge in customer demand in 2020 as a result of the COVID-19 pandemic. In addition, gross profit is being negatively impacted by significant increases in ocean freight and other transportation costs as well as higher than normal increases in raw material costs which change at a significantly faster pace than the Company can sometimes fulfill order backlog. Our portfolio of products has been affected by much higher than normal increases in raw material costs. In the current environment, cost increases may rise more rapidly than our sales price increases, which could decrease gross profit.
https://finance.yahoo.com/news/alpha-pro-tech-ltd-announces-130000252.html
But actually, its hard for me to think that these failed biotechs can go much lower
I'm currently watching about 30 cashfat-biobusts with a pps at, near, or below cash. Trading a few but only smallish trading as I believe several of them will trend much lower as this year 2021 comes to an end.
Couple chart examples with most every shareholder (in the past year) able to take a loss - RFL & ADVM:
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=advm&insttype=&freq=1&show=&time=8
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=rfl&insttype=&freq=1&show=&time=8
CPSS 7.08 - looking good. On a separate subject...do you intend to issue another one of your infamous tax-loss-candidate lists this year (looking forward to it)?
Also, when does everyone start to focus on buying their tax-loss-candidates? Right now, mid-November, wait until December, other?
CPSS 6.45 - just read the CC...numbers are striking and management remains positively giddy:
...So again, real good numbers there. Not to be outdone, servicing continues very strong. Everybody's -- a lot of -- there's a lot of talk about the pandemic, and the stimulus. Stimulus is kind of over at this point. And yet, our collection still remains very, very strong...
...And so that's kind of baked into those numbers from last year. Diluted earnings per share $0.52 is a 33% increase over the $0.39 from our second quarter this year, and a 225% increase over the $0.16 we posted in the third quarter of 2020. Year-to-date numbers, $1.12 for the nine months ended September of this year, compared to $0.74, a 51% increase over the first nine months of last year...
...I think time will tell but it certainly became a little more interesting market. And people are beginning to realize the benefit of these platforms. And obviously, we've been a long time and our platform is very well built and becoming more successful by the day. I also mentioned we bought that stock, the 2 million shares, we've actually bought another half million shares this quarter...
https://docoh.com/transcript/889609/2021Q3/CPSS
CPSS 6.40 - added 6.35 this morning...intend to read the CC later...as solid of a risk/reward-value-stock that I see at $6 pps. And with the wholesale loan used car market looking to be strong for many months ahead.
CPSS in with .52 eps. CC tomorrow at 1:00...
https://docoh.com/news/benzinga/23672261/cps-announces-third-quarter?fromCompany=889609
CPSS 6.53 - nice trade. You might have a point about rising interest rates...but my crystal ball is showing used-car-sales to be a possible blowout with future guidance of more used-car-sales blowout?
New Car Stock Is Still Awful...Many are predicting it won’t be until sometime in 2023 that new car production returns to normal.
https://www.yahoo.com/now/car-stock-still-awful-180000533.html
CPSS 6.63 - reports Q3 tomorrow...
https://finance.yahoo.com/news/cps-host-conference-call-third-183500719.html
SKAS 2.54 - new bid of '10K @ $2.60' while having an average daily volume of 213 shares.
https://www.otcmarkets.com/stock/SKAS/quote
Might be wade deciding to wade into some low volume VALUE, perhaps???
ADVM 2.58 in afterhours on late Friday news:
https://docoh.com/news/benzinga/23202094/adverum-presents-2-year?fromCompany=1501756
Also what is "Zebra's Law"?
Nice call on PALT but I missed the run trying to catch a dip to 2.70...oh well...what I see now in PALT's ludicrous pps-run is just more evidence this market is primed for a serious reality check
SGMA 8.80 - also like 8's.
It's all confusing and dd into the BNTX filings shows BNTX with many future irons in the fire, undoubtedly some partnering with Genevant. So longerterm, the partnership with BNTX might realize revenue?
And this from the GRTS 10-K - page 33:
License Agreement with Arbutus Biopharma Corporation
...As part of our collaboration, we have identified an LNP formulation that we believe will be optimal for use in our Phase 1/2 clinical trial of GRANITE and SLATE. This LNP formulation is currently being used by third parties in human clinical trials in the United States...
https://docoh.com/filing/1656634/0001564590-21-012260/GRTS-10K-2020FY
Who knew? And the filing is from March...
If Genevant sublicenses the intellectual property, licensed by us to Genevant, we are entitled to receive upon the commercialization of a product developed by such sublicensee the lesser of 20% of the revenue received by Genevant for sublicensing and tiered, low single-digit royalties on product sales by the sublicensee.
Does this mean we can eliminate PFE/BNTX from providing any revenue whatsoever to ABUS as ABUS has not recorded any revenue from Genevant to date? And the PFE/BNTX-vaccine has been commercialized for several quarters?
Welp, do you reckon it's so many vendors with so many shares selling this morning? More showing their 'true colors'...getting 'what they deserve'???
GLTO - added today at 3.83...appears GLTO should try to hire away NNVC's pr, promo, n prop crew, ya think?
Galecto's GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients
https://docoh.com/news/benzinga/21665863/galectos-gb0139-shows?fromCompany=1800315
NNVC 6.30 - always thought NNVC was one of the more scammy bio's but they have built up a sizeable cash warchest thru all the covid pr's. It looks like your best outcome would be for them to do a healthy secondary @ $6+ into this ludiculous volume because I seriously doubt anyone will be able to corroborate their fish-story with a reciprocal pr from GILD (remdesivir)?
Might get interested in the $4's...just my two cents
Get up on in there, hweb, sign up n see if you can catch nuthin...lol
I agree, the numbers are pretty good for such a low-share-structure-tiny-market-cap-company in such a dyno sector with such HUGE potential. I signed up and will dig into the site and the fundys further...
PALT 3.06 - interesting...
https://www.paltalk.com/people/webapp/index.wmt
Has anyone become a member and could offer comments on the paltalk website? At first glance it appears to be a risque-hook-up-site...
Thanks value and I'll be focusing in on GME as the overall-barometer-stock for guaging the broad-markets?
GME - I can't recall any stock-pps failing so many 'value' tests so badly!
HBP - added 5.07 yesterday...recent Q of .54 eps and a not-so-distant buyout offer...
GLTO 4.03 - bought the dip at today's close. Another cashfatbiobust trading way less than cash...with a few irons on the fire, more specifically:
Galecto's GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients
https://docoh.com/news/benzinga/21665863/galectos-gb0139-shows?fromCompany=1800315
Yes, I also saw some very peculiar trading activity of several stocks, up & down, in the closing minutes but don't think it had anything to do with options-expiration...and SNFCA doesn't offer option trading?
SNFCA 8.97 (+.91) - very strong close...
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=snfca&insttype=&freq=9&show=&time=1
https://www.nasdaq.com/market-activity/stocks/snfca/latest-real-time-trades
Someone/group snatched a sizeable chunk right at the close? What's up with that?
'...this is a pandemic of the unvaccinated not anything else right now...'
I'm still holding about 70% of my investment-poke in cash even though several stocks on my watch are hitting my buy targets? This market is sooooooo primed to suffer some prolonged devastation and I'm guessing (knowing) these gullible-robinhooligans will jump ship more aggressively than they originally climbed aboard?
One more question:
Is GME at $200 the most (non-outright-scam) OBVIOUS short-proposition we have ever seen in our lifetimes?
In 2020, the death of old and sick people was declared… impermissible! Death suddenly had no place in the exceptional order of things American.
https://kunstler.com/clusterfuck-nation/ordeal-by-narrative/
OVID 3.48 - setup for a freeroll???
$3 netcash-per-share?
Takeda, going forward, to incur all research expenses?
Two Phase-3-commencement announcement catalysts upcoming in 2021?
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.
https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
OVID 3.48 - setup for a freeroll???
$3 netcash-per-share?
Takeda, going forward, to incur all research expenses?
Two Phase-3-commencement announcement catalysts upcoming in 2021?
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.
https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
OVID 3.48 - setup for a freeroll???
$3 netcash-per-share?
Takeda, going forward, to incur all research expenses?
Two Phase-3-commencement announcement catalysts upcoming in 2021?
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.
https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
APT 7.62 - took a small loss on my previous stab at this one. Also I was not impressed with the recent numbers and after watching the college football stadiums the past two weekends...ditching the silly corona-kookout-maskerade...APT belongs back on the back heap of somewhere around $5 or less fair-value-pps imo.
CPSS 5.25 - doubled-down. BV $6.50, quarterly eps of $.39, recent buyout offer, hitting on all cylinders,
https://ir.consumerportfolio.com/news-releases/news-release-details/cps-announces-second-quarter-2021-earnings
and the used-car-market would appear to be getting even stronger as we hear new reports, daily, of 'chip shortages' and 'supply chain' disruptions?
What happen to sub royalties from Genevant
Great question? The Genevant website lists some substantial partnerships!
https://www.genevant.com/partnering/
But I can't find any revenue shown in ABUS filings coming from Genevant...